Furthermore, in animal models of PD, inhibition of mTOR using rapamycin or Temsirolimus (CCI-779) were able to prevent dyskinesia triggered by long-term usage of l-DOPA, a treatment used to manage motor symptoms in PD (Decressac and Bjorklund, 2013, Santini et al., 2009, Subramaniam et al., 2011). Here, MTOR is linked to Parkinson disease.